The role of 5-HT1B/1D receptors in the treatment of migraine

CNS Spectrums

Volumn 3, Issue 8, 1998, Pages 30-39

  Waeber, Christian ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

5 CARBAMOYLTRYPTAMINE; 5 METHYLAMINOSULFONYLMETHYL 3 (1 METHYL 2 PYRROLIDINYLMETHYL) 1H INDOLE; ALMOTRIPTAN; ALNIDITAN; ANTIMIGRAINE AGENT; CP 122638; DIHYDROERGOCORNINE; ELETRIPTAN; ERGOTAMINE; IS 151; LY 334864; N [4 METHOXY 3 (4 METHYL 1 PIPERAZINYL)PHENYL] 2' METHYL 4' (5 METHYL 1,2,4 OXADIAZOL 3 YL)[1,1' BIPHENYL] 4 CARBOXAMIDE; NARATRIPTAN; RIZATRIPTAN; SEROTONIN 1B RECEPTOR; SEROTONIN 1D RECEPTOR; SEROTONIN 5 O CARBOXYMETHYLGLYCYLIODOTYROSINAMIDE; SEROTONIN AGONIST; SEROTONIN ANTAGONIST; SUMATRIPTAN; UNCLASSIFIED DRUG; ZOLMITRIPTAN;

BINDING AFFINITY; DISEASE MODEL; DRUG EFFICACY; DRUG RECEPTOR BINDING; EXTRAVASATION; GENE EXPRESSION; HUMAN; MIGRAINE; NEUROGENIC INFLAMMATION; NONHUMAN; ONCOGENE C FOS; PATHOPHYSIOLOGY; PRIORITY JOURNAL; REVIEW; TRIGEMINAL NUCLEUS;

EID: 0032455469     PISSN: 10928529     EISSN: None     Source Type: Journal    
DOI: 10.1017/S1092852900006313     Document Type: Article

References (44)

1. Llpton RB, Stewart WE Epidemiology and comorbidity of migraine. In: Goadsby PJ, Silberstein SD, eds. Headache. Boston, Mass: Butterworth-Heinemann; 1997:75-95.
2. Ferrari MD, Saxena PR. On serotonin and migraine: a clinical and pharmacological review. Cephalalgia. 1993;13:151-165.
3. Hoyer D, Clarke DE, Fozard JR, et al. Seventh International Union of Pharmacology classification of receptors for 5-hydroxytryptamine (serotonin). Pharmacol Rev. 1994;46:157-203.
4. Fozard JR, Kalkman HO. 5-Hydroxytryplamine (5-HT) and the initiation of migraine: new perspectives. Naunyn Schmiedeberg's Arch Pharmacol. 1994;350:225-229.
5. Graham JR, Volff HG. Mechanism of migraine headache and action of ergolamine tartrate. Arch Neural Psychiatry. 1938;39:737-763.
6. Saxena PR, Tfelt-Hansen P. Sumatriptan. In: Olesen J, Tfelt-Hansen P, Welch KMA, eds. The Headaches. New York, NY: Raven Press; 1993:329-341.
7. Moskowitz MA. Neurogenic versus vascular mechanisms of sumatriptan'and ergot alkaloids in migraine. Trends Pharmacol Sei. 1992;13:307-311.
8. Ray BS, Wolff HG. Experimental studies on headache: pain-sensitive structures of the head and their significance in headache. Arch Surg. 1940;41:813-856.
9. Bove GM, Moskowitz MA. Trigeminal organization with special reference to the trigeminovascular system and cranial pain. In: Yaksh TL, Lynch C III, Zapol WM, Maze M, Biebuyck JF, Saidman LJ, eds. Anesthesia: Biologic Foundations.-Philadelphia, Pa: LippincottRaven; 1997:859-868.
10. Scharff L, Turk DC, Marcus DA. Triggers of headache episodes and coping responses of headache diagnostic groups. Headache. 1995;35:397-403.
11. Ophoff RA, Terwindt GM, Yergouwe MN, et al. Familial hémiplégie migraine and episodic ataxia type-2 are caused by mutations in the Ca2+ channel gene CACNL1A4. Cell. 1996;87:543-552.
12. Page IH, McCubbin MD. The variable arterial pressure response to serotonin in laboratory animals and man. CircRes. 1953;l:354-362.
13. ]D Receptors: pharmacology and therapeutic potential. Serotonin. 1996;l:19-29.
14. 1D/1B receptors. Eur J Pharmacol. 1993;242:75-82.
15. Hamel E, Fan E, Linville D, Ting V, Villemure JG, Chia LS. Expression of mRNA for the serotonin 5-hydroxytryptaminejp/jg receptor subtype in human and bovine cerebral arteries. Mol Pharmacol. 1993;44:242-246.
16. Bouchelet I, Cohen Z, Case B, Séguéla P, Hamel E. Differential expression of sumatriptan-sensitive 5-hydroxytryptamine receptors in human trigeminal ganglia and cerebral blood vessels. Mol Pharmacol. 1996:50:219-223.
17. 1 agonist, on the systemic pulmonary and coronary circulation. Circulation. 1993;87:401-405.
18. 1D- serotonin receptor gene expression in Irigeminal ganglia: implications for antimigraine drug development. Proc t\atl Acad Sei USA. 1994;91:3666-3669.
19. 1B-immunoreactivity within the human trigemino-cerebrovascular system: implications for the discovery of new antimigraine drugs. Cephalalgia. 1997;17:833-842.
20. Ullmer C, Schmuck K, Kalkman HO, Lübbert H. Expression of serotonin receptor mRNAs in blood vessels. FEES Lett. 1995;370:215-221.
21. Markowitz S, Saito K, Moskowitz MA. Neurogenically mediated leakage of plasma protein occurs from blood vessels in dura mater but not brain. / Neurosci. 1987;7:4129-4136.
22. Saito K, Markowitz S, Moskowilz MA. Ergot alkaloids block neurogenic extravasation in dura mater: proposed action in vascular headaches. Ann Neural. 1988;24:732-737.
23. Buzzi MG, Moskowitz MA. The antimigraine drug, sumatriptan (GR43175), selectively blocks neurogenic plasma extravasation from blood vessels in dura mater. Br J Pharmacol. 1990;99:202-206.
24. Buzzi MG, Moskowitz MA, Peroutka SJ, Byun B. Further characterization of the putative 5-HT receptor which mediates blockade of neurogenic plasma protein extravasation in rat dura mater. Br J Pharmacol. 1991;103:1421-1428.
25. 1F receptor agonists inhibit neurogenic durai inflammation in guinea pigs. Neuroreport. 1997;8:2237-2240.
26. Phebus LA, Johnson KW, Zgombick JM, et al. Characterization of LY344861 as a pharmacological tool to study 5-HTjp receptor: binding affinities, brain penetration and activity in the neurogenic durai inflammation model of migraine, life Sei. 1997;61:2117-2126.
27. Pauwels PJ, Tardif S, Palmier C, Wurch T, Colpaert FC. How efficacious are 5-HTjgj receptor ligands: an answer from GTPyS binding studies with stably transfected C6-glial cell lines. Neuropharmacology. 1997;36:499-512.
28. Lee WS, Moskowitz MA. Conformationally restricted sumatriptan analogues, CP-122,288 and CP-122,638 exhibit enhanced potency against neurogenic inflammation in dura mater. Brain Res. 1993;626:303-305.
29. Skingle M, Beattie DT, Scopes DIG, et al. GR127935: a potent and selective 5-HT1D receptor antagonist. Behav Brain Res. 1996;73:157-161.
30. Yu X-J, Cutrer FM, Moskowitz MA, Waeber C. The 5-HT1D receptor antagonist GR-127,935 prevents inhibitory effects of sumatriptan but not CP-122,288 and 5-CT on neurogenic plasma extravasation within guinea pig dura mater. Neuropharmacology. 1996;36:8391.
31. Sl.Saudou F, Amara DA, Dierich A, et al. Enhanced aggressive behavior in mice lacking 5-HT]B receptor. Science. 1994;265:1875-1878.
32. Yu X-J, Waeber C, Castanon N, et al. 5-carboxamidotryptamine, CP-122,288 and dihydroergotamine but not sumatriptan, CP-93,129 and serotonin-5-O-carboxymelhyl-glycyl-tyrosinamide block durai plasma protein extravasation in knockout mice that lack 5-hydroxytryptamine]B receptors. Mol Pharmacol. 1996;49:761-765.
33. Waeber C, Grailhe R, Yu XJ, Hen R, Moskowitz MA. Putative 5-HT5 receptors: localization in the mouse CNS and lack of effect in the inhibition of durai protein extravasation. Ann NYAcad Sei. In press.
34. Sheng M, Greenberg ME. The regulation and function of c-fos and other immediate early genes in the nervous system. Neuron. 1990;4:477-485.
35. Nozaki K, Moskowitz MA, Boccalini P. CP-93,129, sumatriptan, dihydroergotamine block c-fos expression within rat trigeminal nucleus caudalis caused by chemical stimulation of the méninges. Br J Pharmacol. 1992;106:409-415.
36. Nozaki K, Boccalini P, Moskowitz MA. Expression of c-/oi-like immunoreactivity in brain stem after meningeal irritation by blood in subarachnoid space. Neuroscience. 1992;49:669-680.
37. Strassman AM, Vos BP. Somatotopic and laminar organization ofybs-like immunoreactivity in the medullary and upper cervical dorsal horn induced by noxious facial stimulation in the rat. / Comp Neural. 1993;331:495-516.
38. Cutrer FM, Schoenfeld D, Limmroth V, Panahian N, Moskowitz MA. Suppression by the sumatriptan analogue, CP-122,288 of c-fos immunoreactivity in trigeminal nucleus caudalis induced by intracisternal capsaicin. Br J Pharmacol. 1995;! 14:987-992.
39. Shepheard SL, Williamson DJ, Williams J, Hill RG, Hargreaves RJ. Comparison of the effects of sumatriptan and the NK1 antagonist CP-99,994 on plasma extravasation in dura mater and c-fos mRNA expression in trigeminal nucleus caudalis of rats. Neuropharmacology. 1995;34:255-261.
40. Battaglia G, Rustioni A. Coexistence of glutamate and substance P in dorsal root ganglion cells of the rat and monkey. J Comp Neural. 1988;277:302-312.
41. Dougherty PM, Willis WD. Enhancement of spinothalamic neuron responses to chemical and mechanical stimuli following combined microiontophoretic application of N-methyl-D-aspartic acid and substance P. Pain. 1991;47:85-93.
42. Cutrer FM, Moussaoui S, Garret C, Moskowitz MA. The non-peptide neurokinin-1 antagonist, RPR 100893, decreases c-fos expression in trigeminal nucleus caudalis following noxious chemical meningeal stimulation. Neuroscience. 1995;64:741-750.
43. Moskowitz MA, Nozaki K, Kraig RP. Neocortical spreading depression provokes the expression of c-fos protein-like immunoreactivity within trigeminal nucleus caudalis via trigeminovascular mechanisms. JNeurosci. 1993;13:1167-1177.
44. Lauritzen M. Pathophysiology of the migraine aura. The spreading depression theory. Brain. 1994;117:199-210.